Article ID Journal Published Year Pages File Type
2144230 Lung Cancer 2006 8 Pages PDF
Abstract

SummaryPurposeInsulin-like growth factor (IGF) system is related to cell proliferation and tumor growth. We tested whether pretreatment plasma levels of IGF-1, IGF-2, and IGF binding protein (IGFBP)-3 would predict the prognosis in patients with advanced non-small cell lung cancer (NSCLC).MethodsPlasma levels of IGF-1, IGF-2, and IGFBP-3 were measured using enzyme-linked immunoassays from 77 patients with advanced NSCLC enrolled in a phase II study of irinotecan plus cisplatin chemotherapy.ResultsIGF-2 and IGFBP-3 levels were elevated in female patients, non-squamous cell carcinoma, and never smokers. In a univariate Cox proportional hazards model, higher levels of IGF-1, IGF-2, and IGFBP-3 were predictive of longer progression-free (P = 0.001, 0.006, and 0.007, respectively) and overall survival (P = 0.025, <0.0001, and 0.001, respectively). Multivariate analysis revealed that IGF-1 and IGFBP-3 are independent factors for progression-free survival (P < 0.0001 and P = 0.001, respectively). In addition, IGF-1, IGF-2, and IGFBP-3 are independently predictive for overall survival (P = 0.004, 0.001, and 0.043, respectively).ConclusionsHigh plasma levels of IGF-1, IGF-2, and IGFBP-3 were associated with good prognosis in patients with advanced NSCLC. Further validation of these results is needed to determine the prognostic significance of IGF system in advanced NSCLC.

Related Topics
Life Sciences Biochemistry, Genetics and Molecular Biology Cancer Research
Authors
, , , , ,